Guardant Health Inc

GH: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|#cLOCK|>W?LOCK|tRbDvC%

Guardant Health Earnings: Guidance for 2026 Suggests Strong Momentum for Shield; Fair Value Raised

Guardant reported 33% full-year revenue growth. 2026 guidance includes revenue growth of 27%-30%, Shield volume growth of about 150%, a decline in non-GAAP gross profit margin of about 120 basis points at the midpoint, and significantly improved operating expenses and free cash flow.

Sponsor Center